- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04435483
A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single-center, randomized, 3-period, crossover study of acalabrutinib suspension administered via NG tube in healthy subjects to evaluate the relative bioavailability and proton-pump inhibitor (rabeprazole) effect.
The study is divided in 3 periods.
Period 1 of the study is designed to investigate the effect of proton-pump inhibitor on the pharmacokinetics (PK) of acalabrutinib suspension. Period 2 and 3 of the study are designed to investigate the bioavailability of acalabrutinib suspension relative to an oral capsule formulation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Glendale, California, United States, 91206
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study-specific procedures.
- Healthy adult male and female subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
- Male subjects and their female partners/spouses must adhere to the contraception methods.
- Female subjects must have a negative pregnancy test at screening, must not be lactating, and must be of non-childbearing potential.
- Have a body mass index (BMI) between 18.5 and 30 kg/m2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive, at screening.
Exclusion Criteria:
- History or presence of any clinically significant disease (including COVID-19) or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
- Plasma donation within 30 days of screening or any blood donation/loss more than 500 mL during the 90 days prior to screening.
- Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 90 days prior to screening.
- Positive screen for drugs of abuse or cotinine at screening.
- Known or suspected history of alcohol or drug abuse, or excessive intake of alcohol as judged by the Investigator.
- Excessive intake of caffeine-containing drinks or food as judged by the Investigator.
- Vulnerable subjects, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
- History of a disorder which would make NG tube placement contraindicated, eg, esophageal strictures, esophageal varices, or bleeding diathesis.
- Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections). Subjects with localized cutaneous fungal infections are eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Sequence 1
Participants will receive Treatment A (100 mg acalabrutinib suspension via NG administration plus 20 mg rabeprazole) in Period 1, Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 2, and Treatment C (100 mg acalabrutinib capsule) in Period 3.
|
Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension.
Treatment with rabeprazole 20 mg twice daily (with meals) will be started 3 days prior to the receiving the first dose of acalabrutinib suspension.
Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions.
The acalabrutinib capsule will be administered with 240 mL of water.
|
Experimental: Treatment Sequence 2
Participants will receive Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 1, Treatment C (100 mg acalabrutinib capsule) in Period 2, and Treatment B (100 mg acalabrutinib suspension via NG administration) in Period 3.
|
Participants will receive a single dose of 100-mg acalabrutinib suspension via NG administration, under fasted conditions.
Participants will receive a single dose of 100-mg acalabrutinib capsule, under fasted conditions.
The acalabrutinib capsule will be administered with 240 mL of water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acalabrutinib and ACP-5862 plasma PK parameter: Area under plasma concentration-time curve from time zero to infinity (AUCinf)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours (h) post-dose
|
To compare the AUCinf of the acala NG suspension with and without rabeprazole.
To compare the AUC of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours (h) post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the AUClast of the acala NG suspension with and without rabeprazole.
To compare the AUClast of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Maximum observed plasma concentration (Cmax)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the Cmax of the acala NG suspension with and without rabeprazole.
To compare the Cmax of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acalabrutinib and ACP-5862 plasma PK parameter: Area under the plasma concentration-time curve from time zero to 24 hours post-dose (AUC0-24)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the AUC0-24 of the acala NG suspension with and without rabeprazole.
To compare the AUC0-24 of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Time to reach maximum observed plasma concentration (tmax)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the tmax of the acala NG suspension with and without rabeprazole.
To compare the tmax of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the t1/2 of the acala NG suspension with and without rabeprazole.
To compare the t1/2 of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Mean residence time of the drug in the systemic circulation from zero to infinity (MRT)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the MRT of the acala NG suspension with and without rabeprazole.
To compare the MRT of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Terminal elimination rate constant (λz)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the λz of the acala NG suspension with and without rabeprazole.
To compare the λz of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Apparent total body clearance of drug from plasma after extravascular administration (acalabrutinib only) (CL/F)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the CL/F of the acala NG suspension with and without rabeprazole.
To compare the CL/F of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Apparent volume of distribution during the terminal phase after extravascular administration (acalabrutinib only) (Vz/F)
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the Vz/F of the acala NG suspension with and without rabeprazole.
To compare the Vz/F of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Metabolite to parent ratio based on AUCinf and/or AUClast (M:P[AUC])
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the M:P[AUC] of the acala NG suspension with and without rabeprazole.
To compare the M:P[AUC] of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Acalabrutinib and ACP-5862 plasma PK parameter: Metabolite to parent ratio based on Cmax (M:P[Cmax])
Time Frame: Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
To compare the M:P[Cmax] of the acala NG suspension with and without rabeprazole.
To compare the M:P[Cmax] of the acala NG suspension with the oral capsule.
|
Day 1 to 2: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 h post-dose
|
Number of subjects with abnormal vital signs
Time Frame: Screening, Day -1, and Day 2
|
To assess the safety and tolerability of single doses of acalabrutinib suspension in healthy participants.
|
Screening, Day -1, and Day 2
|
Number of subjects with abnormal laboratory assessments
Time Frame: Screening, Day -1, Days 1-2, and follow-up visit (7-10 days after last dose)
|
To assess the safety and tolerability of single doses of acalabrutinib suspension in healthy participants.
|
Screening, Day -1, Days 1-2, and follow-up visit (7-10 days after last dose)
|
Number of subjects with serious and non-serious adverse events
Time Frame: Screening (Day -28), Days -3, -2, -1, Days 1-3, and follow-up visit (7-10 days after last dose)
|
To assess the safety and tolerability of single doses of acalabrutinib suspension in healthy participants.
|
Screening (Day -28), Days -3, -2, -1, Days 1-3, and follow-up visit (7-10 days after last dose)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Han, M.D., PAREXEL Early Phase Clinical Unit-Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D822FC00004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacokinetics
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Methotrexate | Pharmacokinetics of 7-hydroxymethotrexateUnited States
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1941 | Pharmacokinetics of MitiglinideJapan
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MethadoneUnited States
-
Astellas Pharma IncBasilea PharmaceuticaCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MidazolamUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of DigoxinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of BupropionUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of SirolimusUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of AtorvastatinUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Caffeine | Pharmacokinetics of RepaglinideUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
Clinical Trials on Acalabrutinib Treatment A
-
AstraZenecaParexelCompletedCOVID-19 | Mantle Cell LymphomaGermany
-
AstraZenecaCompletedBioequivalenceUnited States
-
Acerta Pharma BVNational Institutes of Health (NIH)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
AstraZenecaAcerta Pharma BVCompletedCOVID-19Italy, Turkey, Brazil, Japan, South Africa, Germany, Poland, Russian Federation, India, Peru, France, Argentina, Chile, Mexico
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
Acerta Pharma BVAstraZenecaCompletedHepatic Insufficiency | Healthy Subjects | Hepatic ImpairmentUnited States
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompleted